Vulvar Cancer - Pipeline Review, H2 2016


#896050

76pages

Global Markets Direct

$ 2000

In Stock

Vulvar Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2016, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II stages are 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Vulvar Cancer.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vulvar Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Vulvar Cancer - Overview 7
Pipeline Products for Vulvar Cancer - Comparative Analysis 8
Vulvar Cancer - Therapeutics under Development by Companies 9
Vulvar Cancer - Therapeutics under Investigation by Universities/Institutes 10
Vulvar Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Vulvar Cancer - Products under Development by Companies 12
Vulvar Cancer - Products under Investigation by Universities/Institutes 13
Vulvar Cancer - Companies Involved in Therapeutics Development 14
Cutanea Life Sciences Inc 14
ISA Pharmaceuticals BV 15
Ono Pharmaceutical Co Ltd 16
Oryx GmbH & Co KG 17
PDS Biotechnology Corp 18
Vulvar Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ISA-101 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
nivolumab - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
omiganan pentahydrochloride - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
PDS-0101 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Vicoryx - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Vulvar Cancer - Dormant Projects 72
Vulvar Cancer - Product Development Milestones 73
Featured News & Press Releases 73
Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 73
Mar 07, 2011: ISA Pharma Receives 2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 73
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 73
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables
Number of Products under Development for Vulvar Cancer, H2 2016 7
Number of Products under Development for Vulvar Cancer - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H2 2016 14
Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2016 15
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 16
Vulvar Cancer - Pipeline by Oryx GmbH & Co KG, H2 2016 17
Vulvar Cancer - Pipeline by PDS Biotechnology Corp, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Vulvar Cancer - Dormant Projects, H2 2016 72

List of Figures
Number of Products under Development for Vulvar Cancer, H2 2016 7
Number of Products under Development for Vulvar Cancer - Comparative Analysis, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Molecule Types, H2 2016 26
Number of Products by Stage and Molecule Types, H2 2016 26